The data will support filings with regulatory bodies, starting with the FDA later this year.
News
AbbVie, Allergan megamerger set for May close
Despite the two businesses putting planning in place, Bloomberg recently reported that mergers in the US may face further delays due to the COVID-19 outbreak.
Oxford Biomedica to license LentiVector to Juno
The deal makes the platform available for application in Juno’s CAR-T and TCR-T programmes in oncology and other indications.
Imfinzi, tremelimumab combo flunks SCLC trial
Data from the Phase III CASPIAN trial has shown that the addition of tremelimumab to Imfinzi did not significantly improve overall survival.
Higher dose of gefapixant hits endpoints in chronic cough trial
On the other hand, the gefapixant 15mg twice daily treatment arms did not meet the primary efficacy endpoint.
COVID-19: Pfizer, Regeneron to develop candidates, but solution likely to ‘be a year away’
As the case count for COVID-19 (coronavirus) in the UK hits 1950, pharma companies continue to pitch in with their efforts.
COVID-19: Sanofi, Moderna, BioNTech give updates
The announcements follow government issued advice to avoid all non-essential travel and contact in the UK.
Novo cancels haemophilia drug Phase III trial
Haemophilia is a mostly inherited genetic disorder that impairs the body’s ability to make blood clots.
New research discovers cells linked to Alzheimer’s and autism
The new insight into the architecture of the brain is the most in-depth study of its kind.
PrEP to be available in England from April
Local authorities will receive £16 million in 2020 to 2021 to deliver the preventative HIV treatment.
Jardiance bags FDA Fast Track designation
The decision follows a Jardiance Fast Track designation which was granted by the FDA in July 2019 for the risk of cardiovascular death.
Risk of death by stroke down 24%
Stroke is the fourth single leading cause of death in England and Wales.
Pancreas app now available for type I diabetics in UK
The launch is a “major stepping stone” towards providing “widely available, clinically proven, and user friendly artificial pancreas technology to people with type I diabetes.”
Merck, Pfizer terminate Bavencio head and neck cancer trial
The decision follows advice from the trial’s independent data monitoring committee.
COVID-19: Eli Lilly, Elsevier hop on board
Eli Lilly and AbCellera have plans to co-develop antibody products, and Elsevier is set to make all of its research and data content available on PubMed.
